SCHEMBL3514847

SCHEMBL3514847

O=Cc1ccc(OP(=O)(O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 4/20 0.61
INPPL1 O15357 3/20 0.50
INPP5A Q14642 3/20 0.50
ALDH1A1 P00352 2/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CYP2A6 P11509 1/20 0.50
BLM P54132 1/20 0.48
DRD1 P21728 1/20 0.46
ALDH1A3 P47895 1/20 0.45
ALDH5A1 P51649 1/20 0.44
ABAT P80404 1/20 0.44
KMT2A Q03164 2/20 0.44
PARP10 Q53GL7 1/20 0.44
PARP3 Q9Y6F1 1/20 0.44
STS P08842 1/20 0.44
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11217365 0.83 ALDH1A1 (0.47) SRCALDH1A1CYP2A6DRD1ALDH1A3
SCHEMBL329313 0.83 SRC (0.75) SRCINPPL1INPP5ACA1CA2
SCHEMBL3516747 0.82 ALDH1A1 (0.54) SRCALDH1A1CYP2A6DRD1ALDH1A3
Ammonia Solution, Strong SCHEMBL10714477 0.81 SRC (0.71) SRCINPPL1INPP5ACA1CA2
SCHEMBL8676949 0.81 SRC (0.54) SRCINPPL1INPP5AALDH1A1CA1
SCHEMBL11217369 0.81 ALDH1A1 (0.48) SRCALDH1A1CYP2A6DRD1ALDH1A3
SCHEMBL13858750 0.78 ALDH1A1 (0.56) ALDH1A1CYP2A6DRD1ALDH1A3ALDH5A1
SCHEMBL21800987 0.78 ALDH1A1 (0.50) SRCALDH1A1CYP2A6DRD1ALDH1A3
SCHEMBL11666095 0.78 SRC (0.50) SRCINPPL1INPP5AALDH1A1CA1
SCHEMBL9019350 0.78 SRC (0.67) SRCINPPL1INPP5ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009068321-A1 SITE-DIRECTED HIGH THROUGHPUT SCREENING FORSCHUNGSVERBUND BERLIN E.V. (DE) 2009-06-04 WO claimed
CN-111954525-B Prodrugs of fused bicyclic C5aR antagonists 凯莫森特里克斯股份有限公司 2023-12-26 CN disclosed
US-11608336-B2 Prodrugs of fused-bicyclic C5aR antagonists CHEMOCENTRYX, INC. (US) 2023-03-21 US disclosed
CN-111876098-B Amphiphilic ionomer-reinforced healthy environment-friendly hot melt adhesive and preparation and application thereof 广东泰强化工实业有限公司 2021-10-22 CN disclosed
EP-3523297-B1 NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER UNIV BERLIN FREIE (DE) 2021-07-07 EP disclosed
US-20210052612-A1 PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2021-02-25 US disclosed
EP-3773563-A1 PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2021-02-17 EP disclosed
CN-111954525-A Prodrugs of fused bicyclic C5aR antagonists 凯莫森特里克斯股份有限公司 2020-11-17 CN disclosed
CN-111876098-A Amphiphilic ionomer-reinforced healthy environment-friendly hot melt adhesive and preparation and application thereof 广东泰强化工实业有限公司 2020-11-03 CN disclosed
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed
EP-2001886-A2 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2008-12-17 EP disclosed
EP-1641807-B1 AROMATIC COMPOUNDS AS ALDOLASE INHIBITORS UNIV TOULOUSE (FR) 2008-06-18 EP disclosed
WO-2008020813-A1 METHOD OF ELECTRICALLY DETECTING A BIOLOGICAL ANALYTE MOLECULE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2008-02-21 WO disclosed
WO-2007103839-A2 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-13 WO disclosed
US-20070213300-A1 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-09-13 US disclosed
US-20070043002-A1 Aldolase-inhibiting aromatic compounds UNIVERSITE PAUL SABATIER TOULOUSE III (FR) 2007-02-22 US disclosed
EP-1641807-A2 AROMATIC COMPOUNDS AS ALDOLASE INHIBITORS UNIVERSITE PAUL SABATIER TOULOUSE III (FR) 2006-04-05 EP disclosed
WO-2005012313-A2 ALDOLASE-INHIBITING AROMATIC COMPOUNDS UNIVERSITE PAUL SABATIER TOULOUSE III (FR) 2005-02-10 WO disclosed
EP-0487343-B1 Process for preparing a lithographic plate FUJI PHOTO FILM CO LTD (JP) 1999-04-28 EP disclosed
EP-0487343-A1 Process for preparing a lithographic plate Fuji Photo Film Co., Ltd. (JP) 1992-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11608336-B2 Prodrugs of fused-bicyclic C5aR antagonists C5AR2, C5AR1, C3AR1 SRC 1948/4885INPPL1 538/4885INPP5A 462/4885
US-20070043002-A1 Aldolase-inhibiting aromatic compounds ALDOA, DERA, AKR1B1 SRC 3453/4885INPPL1 1864/4885INPP5A 1813/4885
US-20210052612-A1 PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS C5AR2, C5AR1, C3AR1 SRC 1948/4885INPPL1 538/4885INPP5A 462/4885
US-20070213300-A1 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS CDK2, CDK3, CDK1 SRC 299/4885INPPL1 736/4885INPP5A 1329/4885
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 SRC 16/4885INPPL1 639/4885INPP5A 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.